← Leaderboards
Douglas K Graham
University Of Colorado Denver
$6,579,169
Attributed
$10,138,039
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,138,039 · 8
By mechanism
R01$6,629,857 · 4
P50$1,911,401 · 2
T32$1,440,781 · 1
R03$156,000 · 1
Top collaborators
- Xiaodong Wang10 shared
- Stephen Patrick Hunger4 shared
- Dmitri Kireev2 shared
- Muxiang Zhou2 shared
- Dawn Elizabeth Barnes1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Issam A Awad$18,526,491
- Elizabeth J Shpall$12,617,686
- Hae J Park$153,008
- Amanda C Winters$683,699
- Erin Nicole Howe$175,445
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsPharmaceutical PreparationsMalignant NeoplasmsReceptor Protein-Tyrosine KinasesXenograft ModelQuality Of LifeMediatingTargeted TreatmentTherapeutic TargetResistanceOncogenicMertk GenePre-ClinicalTumorToxic EffectCytotoxic ChemotherapyCell SurvivalNeoplasm MetastasisCancer TherapyInnate Immune ResponseNeoplastic CellCancer ModelClinical ApplicationClinical Trials
Grant awards (28)
Discovery of a novel MDM2-tubulin signaling pathway as a therapeutic target in AML$538,185
R01 · FY2025 · CA
Novel TYRO3 inhibitors for treatment of cancer$323,080
R01 · FY2025 · CA
Discovery of a novel MDM2-tubulin signaling pathway as a therapeutic target in AML$554,143
R01 · FY2024 · CA
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity$463,267
R01 · FY2024 · CA
Novel TYRO3 inhibitors for treatment of cancer$306,926
R01 · FY2024 · CA
Project 2: Targeting MERTK to improve outcomes for EGFR-mutated NSCLC$128,039
P50 · FY2024 · CA · contact PI
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity$497,060
R01 · FY2023 · CA
Project 2: Targeting MERTK to improve outcomes for EGFR-mutated NSCLC$354,544
P50 · FY2023 · CA · contact PI
Novel TYRO3 inhibitors for treatment of cancer$316,619
R01 · FY2023 · CA
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity$497,060
R01 · FY2022 · CA
Project 2: Targeting MERTK to improve outcomes for EGFR-mutated NSCLC$377,671
P50 · FY2022 · CA · contact PI
Novel TYRO3 inhibitors for treatment of cancer$316,619
R01 · FY2022 · CA
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity$507,204
R01 · FY2021 · CA
Project 2: Targeting MERTK to improve outcomes for EGFR-mutated NSCLC$349,448
P50 · FY2021 · CA · contact PI
Novel TYRO3 inhibitors for treatment of cancer$336,957
R01 · FY2021 · CA
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity$521,079
R01 · FY2020 · CA
Project 2: Targeting MERTK to improve outcomes for EGFR-mutated NSCLC$363,004
P50 · FY2020 · CA · contact PI
A Targeted Combination Therapy Approach for AML$156,000
R03 · FY2020 · CA · contact PI
Project 2: Targeting MERTK to improve outcomes for EGFR-mutated NSCLC$338,695
P50 · FY2019 · CA · contact PI
Post Graduate Training in Pediatric Oncology$386,519
T32 · FY2014 · CA · contact PI
Novel Biologically Targeted Therapy Against the Mer and Axl Receptor Tyrosine Kin$288,366
R01 · FY2014 · CA · contact PI
Post Graduate Training in Pediatric Oncology$358,852
T32 · FY2013 · CA · contact PI
Novel Biologically Targeted Therapy Against the Mer and Axl Receptor Tyrosine Kin$279,446
R01 · FY2013 · CA · contact PI
Post Graduate Training in Pediatric Oncology$374,504
T32 · FY2012 · CA
Novel Biologically Targeted Therapy Against the Mer and Axl Receptor Tyrosine Kin$297,284
R01 · FY2012 · CA · contact PI
Post Graduate Training in Pediatric Oncology$320,906
T32 · FY2011 · CA
Novel Biologically Targeted Therapy Against the Mer and Axl Receptor Tyrosine Kin$284,483
R01 · FY2011 · CA · contact PI
Novel Biologically Targeted Therapy Against the Mer and Axl Receptor Tyrosine Kin$302,079
R01 · FY2010 · CA · contact PI